Background The approval of the HPV vaccine in 2006 ushered in an unprecedented era as
a tool to prevent cervical cancer, in addition to other human papillomavirus (HPV)–caused …

In the recent period following the approval of the first vaccine targeted against human
papillomavirus, it is imperative that we re-evaluate the past, present, and future of cervical …

Since the introduction of the HPV vaccine, questions have been asked about its efficacy in
preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have …

Approximately 250,000 women die every year of cervical cancers caused by human
papillomavirus (HPV). Most of these could have been prevented by the currently available …

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a
necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could …

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its
toll is greatest in populations that lack screening programmes to detect precursor lesions …

The discovery of the association between infection by the human papillomavirus (HPV) and
the development of cervical cancer has been the foundation for establishing HPV as the …

The HPV vaccine: Understanding and addressing barriers to vaccination. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

Globally, cervical cancer is second only to breast cancer as the leading cause of cancer in
women, with a global prevalence of 2.3 million. It is the third most common cause of female …

Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent
carcinogenesis. The identification of this obligate viral etiology, in addition to a vast …